AstraZeneca cut to Sell by Deutsche Bank on pipeline doubts, patent risk
NegativeFinancial Markets
AstraZeneca has been downgraded to a 'Sell' rating by Deutsche Bank due to concerns over its drug pipeline and potential patent risks. This decision reflects growing skepticism about the company's ability to deliver new products and maintain its market position. Investors should pay attention to these developments as they could impact AstraZeneca's future performance and stock value.
— Curated by the World Pulse Now AI Editorial System